Dr Emily Lelliott
Honorary (Fellow)
The Sir Peter MacCallum Department of Oncology
23 Scholarly works
2 Projects
HIGHLIGHTS
2026
Journal article
CDK4/6 inhibition enhances CAR-T cell therapy in solid tumors
DOI: 10.1016/j.ymthe.2026.03.0242026
Journal article
A TAK1 cytokine toxicity checkpoint controls anti-cancer immunity
DOI: 10.1016/j.celrep.2025.1166652025
Journal article
Advancing the genetic engineering toolbox by combining AsCas12a knock-in mice with ultra-compact screening
DOI: 10.1038/s41467-025-56282-22025
Journal article
3107 – ADVANCED CRISPR KNOCKOUT AND ACTIVATION MOUSE MODELS AS TOOLS FOR INVESTIGATING HEMATOLOGY AND HEMATOLOGICAL MALIGNANCIES
DOI: 10.1016/j.exphem.2025.1050482025
Research grants (ARC, NHMRC, MRFF)
Uncovering New Targets for Cancer Immunotherapy Through Multiplexed Genomic Screens in Cytotoxic T Cells
2025
Journal article
Sensitivity to immune checkpoint inhibitors in BRAF/MEK inhibitor refractory melanoma
DOI: 10.1136/jitc-2025-0115512025
Research grants (ARC, NHMRC, MRFF)
Unravelling the Molecular Basis of CD8+ T Cell Development and Behaviour
RECENT SCHOLARLY WORKS
2025
Journal article
Genome-wide in vivo CRISPR screens identify GATOR1 complex as a tumor suppressor in Myc-driven lymphoma
DOI: 10.1038/s41467-025-62615-y2024
Journal article
Intracellular zinc protects tumours from T cell-mediated cytotoxicity
DOI: 10.1038/s41418-024-01369-42023
Journal article
Sequencing of targeted- and immune-therapy: delineating time dependent changes in both melanoma cells and the immune microenvironment
DOI: 10.1158/1538-7445.AM2023-59412022
Journal article
Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?
DOI: 10.1038/s41698-022-00273-92022
Journal article
Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAFV600 melanoma
DOI: 10.1038/s41467-022-28705-x